Differential mechanisms of action of interferon-β and glatiramer acetate in MS
- 24 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 59 (6) , 802-808
- https://doi.org/10.1212/wnl.59.6.802
Abstract
Interferon-beta and glatiramer acetate (GA) are the two main groups of drugs used in the treatment of MS. Notably, while both ultimately decrease CNS inflammation, they do so by very different mechanisms. Interferon-beta has potent activity at the blood-brain barrier and impairs the trafficking of inflammatory cells into the CNS. In contrast, GA has negligible effect at the blood-brain barrier, allowing GA-specific T helper 2 lymphocytes to enter the CNS to decrease inflammation through bystander suppression. Other differences are also emphasized. The presence of GA-reactive lymphocytes within the CNS parenchyma may have the additional benefit of conferring neuroprotection through protective autoimmunity.Keywords
This publication has 49 references indexed in Scilit:
- Glatiramer acetate and IFN-β act on dendritic cells in multiple sclerosisJournal of Neuroimmunology, 2001
- Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genesAnnals of Neurology, 2001
- Interferon-β therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosisJournal of Neuroimmunology, 2001
- Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4Journal of Neuroimmunology, 2000
- Multiple sclerosis:: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-βJournal of Neuroimmunology, 2000
- RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-β-1bJournal of Neuroimmunology, 2000
- In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomenaAnnals of Neurology, 2000
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosisJournal of Clinical Investigation, 2000
- Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation?The Journal of Experimental Medicine, 1999
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998